Can you get medical cannabis for multiple sclerosis in the UK?

Multiple sclerosis is the strongest case on this page, and the only condition here where a cannabis-based medicine is both licensed in the UK and recommended by NICE — for one specific symptom, under specific conditions.

The short answer

  • A THC:CBD oromucosal spray is licensed in the UK for moderate to severe MS spasticity.
  • NICE recommends it where other treatments have not worked, started by a specialist in MS spasticity.
  • A four-week trial rule applies: continue only if spasticity symptoms improve by at least 20%.
  • It treats spasticity, not MS. Disease-modifying therapy is separate and should continue.
  • Other MS symptoms — pain, bladder problems, tremor — are assessed privately and are not licensed uses.

Is multiple sclerosis treated with medical cannabis in the UK?

Yes, for one symptom, on the NHS: moderate to severe spasticity in MS, where other antispasticity medicines have not worked well enough. This is one of only three licensed uses of a cannabis-based medicine in the UK.

NICE guideline NG144 recommends the THC:CBD oromucosal spray for this purpose, with conditions attached. Treatment must be started and supervised by a doctor with specialist expertise in MS spasticity. It runs as a four-week trial, and is continued only if the person's spasticity-related symptoms improve by at least 20% on a patient-reported scale. If they do not, it is stopped.

Other MS symptoms sit outside that licence. Neuropathic pain in MS, bladder dysfunction, tremor, fatigue and sleep problems are assessed by private specialists case by case, on much weaker evidence, in the same way as any other unlicensed use.

None of this is disease-modifying treatment. Cannabis-based medicines do not slow MS progression or reduce relapses, and your neurology team should continue to lead that side of your care.

What the evidence actually shows

MS spasticity has the evidence base the rest of this field lacks: multiple randomised controlled trials, a regulatory licence, and a NICE recommendation. That is why the NHS position on MS is different from its position on everything else.

The pivotal trial used an enriched design — a single-blind run-in phase identified people who responded to the spray, and only those responders were randomised to continue on it or switch to placebo. Among that responder group, the spray was significantly better than placebo on spasticity scores. That design answers a specific question well: does it keep working in people it works for? It also explains the four-week trial rule in NICE guidance. Roughly speaking, it does not help most people who try it, and helps a minority meaningfully — so the sensible policy is to try it briefly and stop unless there is a clear response.

Evidence for other MS symptoms is much weaker, and a specialist should distinguish clearly between the licensed use and everything else.

The study behind that paragraph

Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. European Journal of Neurology. 2011;18(9):1122-1131. The pivotal phase 3 trial: an initial run-in identified responders, who were then randomised; the spray outperformed placebo in that responder group.

Read the paper →

What a specialist will want to see

There is no UK list of qualifying conditions, so nothing here entitles you to a prescription. A specialist works through your history and decides whether a monitored trial is justified for you. For multiple sclerosis they will typically look at:

The general requirements — age, a documented diagnosis, the convention that two standard treatments have been tried, and access to your medical records — are covered in What are the requirements?

Risks and reasons a specialist may say no

Dizziness and fatigue are common with the licensed spray and matter more in MS, where balance and fatigue are often already impaired. Falls are a real consideration.

Cognitive effects deserve attention too: MS itself can affect processing speed and memory, and THC-containing medicines can add to that. A personal or family history of psychosis, unstable serious mental illness, pregnancy and breastfeeding all count against treatment. Driving impairment applies as it does elsewhere, and MS-related visual or motor problems may already affect fitness to drive independently.

If you want to take this further

The useful next step is a proper assessment, not a better list. Gather your diagnosis, the treatments you have already tried and what happened with each, and your current medicines — that is what a specialist needs in order to give you a straight answer.

The consultation itself, and what happens after it, is set out in What is the process to get a medical cannabis prescription? If multiple sclerosis is not the only thing you are being treated for, say so early: other conditions and other medicines change the assessment.

Frequently asked questions

Can I get medical cannabis for MS on the NHS?

Yes, for moderate to severe spasticity where other treatments have not worked. NICE recommends a THC:CBD oromucosal spray, started and supervised by a specialist in MS spasticity, as a four-week trial continued only if spasticity-related symptoms improve by at least 20%.

Does medical cannabis slow down MS?

No. Cannabis-based medicines are not disease-modifying. They do not reduce relapses or slow progression, and they are not a substitute for disease-modifying therapy. Your neurology team should continue to manage that.

What about MS pain, bladder problems or tremor?

Those fall outside the licensed use. Private specialists assess them case by case on much weaker evidence. A clinician should be clear with you about which part of your treatment is licensed and which is not.

Why is there a 20% improvement rule?

Because the pivotal trial showed the spray works well for a minority of people and not for most. NICE therefore recommends a short trial with a defined threshold, so that people who are not benefiting stop rather than continue on a medicine with side effects.

Sources and further reading

Every factual statement on this page is drawn from the following public sources. Links open in a new tab and are not affiliated with Flora House.

  1. Novotna A, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols as add-on therapy in subjects with refractory spasticity caused by multiple sclerosis. European Journal of Neurology (2011)
  2. NICE guideline NG144: Spasticity recommendations
  3. NHS: Multiple sclerosis treatment
  4. NICE guideline NG144: Cannabis-based medicinal products
  5. NHS: Medical cannabis (and cannabis oils)
  6. House of Commons Library briefing CBP-8355: Medical use of cannabis
  7. MHRA: The supply, manufacture, importation and distribution of unlicensed cannabis-based products for medicinal use

Patient guide · Written by the Flora House editorial team · Last reviewed: 31 August 2026